Results 1 to 10 of about 6,155 (206)
The Long-Term Survival of LVAD Patients—A TriNetX Database Analysis
Background: Donor shortage limits the utilization of heart transplantation, making it available for only a fraction of the patients on the transplant waiting list. Therefore, continuous-flow left ventricular assist devices (CF-LVADs) have evolved as a standard of care for end-stage heart failure.
Dongping Du +2 more
exaly +3 more sources
Association of uveitis with pediatric autoimmune diseases based on a TriNetX study
To investigate for the risk of uveitis among such patients. A retrospective cohort study utilized the TriNetX database and recruited pediatric autoimmune patients diagnosed between January 1st 2004 and December 31st 2022.
Alan Y. Hsu +10 more
doaj +3 more sources
Randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy and safety of both pharmacological and non-pharmacological interventions.
Ralf J. Ludwig +20 more
exaly +3 more sources
Objectives: TriNetX is a global network of deidentified electronic health record data that participating healthcare institutions can access and analyze.
Joshua Wang, Kuo-Wang Tsai, Kuo-Cheng Lu
doaj +3 more sources
Introduction Large-scale real-world data (RWD) are increasingly used in clinical and epidemiological research, although database-specific structures and limitations may affect study validity and applicability.
Teng-Li Lin
exaly +3 more sources
Preventive Cardiovascular Medication Prescribing Patterns in Menopausal Women [PDF]
Objective: To characterize longitudinal prescribing patterns of preventive cardiovascular medications among women with nonsurgical menopause and women with surgical menopause to better identify potential differences in care.
Amanda Chang, MD +6 more
doaj +2 more sources
Filtering Geriatric Patients by Age in TriNetX [PDF]
Joshua Wang PhD
doaj +2 more sources
Pseudo-Index Events Cannot be Configured on the TriNetX Platform. [PDF]
Wang J.
europepmc +2 more sources
Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman +4 more
doaj +1 more source

